170 related articles for article (PubMed ID: 35768294)
21. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.
Choi HJ; Kim DG; Na GH; Han JH; Hong TH; You YK
World J Gastroenterol; 2013 Aug; 19(29):4737-44. PubMed ID: 23922471
[TBL] [Abstract][Full Text] [Related]
22. Differences in Posttransplant Hepatocellular Carcinoma Recurrence by Etiology of Liver Disease.
Mahmud N; Shaked A; Olthoff KM; Goldberg DS
Liver Transpl; 2019 Mar; 25(3):388-398. PubMed ID: 30362249
[TBL] [Abstract][Full Text] [Related]
23. Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma.
Shindoh J; Sugawara Y; Nagata R; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Tanaka T; Kokudo N
Transpl Int; 2014 Apr; 27(4):391-8. PubMed ID: 24472068
[TBL] [Abstract][Full Text] [Related]
24. AFP role in predicting recurrence of hepatocellular carcinoma after living donor liver transplantation in HCV patients.
Komorowski AL; Hsu CC; Julka KD; Vasavada B; Lin CC; Wang CC; Chen CL
Neoplasma; 2018 Mar; 65(3):455-460. PubMed ID: 29788730
[TBL] [Abstract][Full Text] [Related]
25. [Study on the value of serum des-γ-carboxy prothrombin in predicting hepatocellular carcinoma recurrence after liver transplantation].
Xu Y; Wang PX; Cheng JW; Huang XW; Zhou J; Fan J; Yang XR
Zhonghua Gan Zang Bing Za Zhi; 2020 Nov; 28(11):918-923. PubMed ID: 33256276
[No Abstract] [Full Text] [Related]
26. Preoperative serum liver enzyme markers for predicting early recurrence after curative resection of hepatocellular carcinoma.
Wang ZX; Jiang CP; Cao Y; Zhang G; Chen WB; Ding YT
Hepatobiliary Pancreat Dis Int; 2015 Apr; 14(2):178-85. PubMed ID: 25865691
[TBL] [Abstract][Full Text] [Related]
27. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.
Sharma P; Welch K; Hussain H; Pelletier SJ; Fontana RJ; Marrero J; Merion RM
Dig Dis Sci; 2012 Mar; 57(3):806-12. PubMed ID: 21953139
[TBL] [Abstract][Full Text] [Related]
28. Alpha-fetoprotein and
Yang Z; Luo FZ; Wang S; Lerut J; Zhuang L; Li QY; Xu X; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):229-234. PubMed ID: 32303439
[TBL] [Abstract][Full Text] [Related]
29. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.
Grąt M; Kornasiewicz O; Lewandowski Z; Hołówko W; Grąt K; Kobryń K; Patkowski W; Zieniewicz K; Krawczyk M
World J Surg; 2014 Oct; 38(10):2698-707. PubMed ID: 24858191
[TBL] [Abstract][Full Text] [Related]
30. Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience.
Varona MA; Soriano A; Aguirre-Jaime A; Garrido S; Oton E; Diaz D; Portero J; Bravo P; Barrera MA; Perera A
Transplant Proc; 2015; 47(1):84-9. PubMed ID: 25645778
[TBL] [Abstract][Full Text] [Related]
31. Higher Bilirubin Levels of Healthy Living Liver Donors Are Associated With Lower Posttransplant Hepatocellular Carcinoma Recurrence.
Han S; Yang JD; Sinn DH; Ko JS; Kim JM; Shin JC; Son HJ; Gwak MS; Joh JW; Kim GS
Transplantation; 2016 Sep; 100(9):1933-8. PubMed ID: 27362316
[TBL] [Abstract][Full Text] [Related]
32. Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma.
Halazun KJ; Rosenblatt RE; Mehta N; Lai Q; Hajifathalian K; Gorgen A; Brar G; Sasaki K; Doyle MBM; Tabrizian P; Agopian VG; Najjar M; Ivanics T; Samstein B; Brown RS; Emond JC; Yao F; Lerut J; Rossi M; Mennini G; Iesari S; Finkenstedt A; Schaefer B; Mittler J; Hoppe-Lotichius M; Quintini C; Aucejo F; Chapman W; Sapisochin G
JAMA Surg; 2021 Jun; 156(6):559-567. PubMed ID: 33950167
[TBL] [Abstract][Full Text] [Related]
33. Non-transplantable recurrence after percutaneous thermal ablation of ≤3-cm HCC: Predictors and implications for treatment allocation.
Gozzo C; Hermida M; Herrero A; Panaro F; Cassinotto C; Mohamad AM; Assenat E; Guillot C; Allimant C; Schembri V; Basile A; Dharancy S; Ursic-Bedoya J; Guiu B
Hepatol Commun; 2022 Oct; 6(10):2975-2987. PubMed ID: 35932178
[TBL] [Abstract][Full Text] [Related]
34. Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study.
Takada Y; Kaido T; Shirabe K; Nagano H; Egawa H; Sugawara Y; Taketomi A; Takahara T; Wakabayashi G; Nakanishi C; Kawagishi N; Kenjo A; Gotoh M; Toyoki Y; Hakamada K; Ohtsuka M; Akamatsu N; Kokudo N; Takeda K; Endo I; Takamura H; Okajima H; Wada H; Kubo S; Kuramitsu K; Ku Y; Ishiyama K; Ohdan H; Ito E; Maehara Y; Honda M; Inomata Y; Furukawa H; Uemoto S; Yamaue H; Miyazaki M; Takada T;
J Hepatobiliary Pancreat Sci; 2017 Jan; 24(1):49-57. PubMed ID: 27806426
[TBL] [Abstract][Full Text] [Related]
35. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.
Lee KW; Yi NJ; Suh KS
Transplantation; 2014 Apr; 97 Suppl 8():S20-3. PubMed ID: 24849825
[TBL] [Abstract][Full Text] [Related]
36. Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation.
Han K; Tzimas GN; Barkun JS; Metrakos P; Tchervenkov JL; Hilzenrat N; Wong P; Deschênes M
Can J Gastroenterol; 2007 Jan; 21(1):39-45. PubMed ID: 17225881
[TBL] [Abstract][Full Text] [Related]
37. Incidence and Risk Factor of Hepatocellular Carcinoma Recurrence After Liver Transplant: Results From a Single Clinic.
Bolkvadze R; Kashibadze K; Nakashidze M; Mikeladze L; Beridze D; Beridze S
Exp Clin Transplant; 2024 Jan; 22(Suppl 1):256-262. PubMed ID: 38385408
[TBL] [Abstract][Full Text] [Related]
38. Liver transplant for hepatocellular carcinoma: experience in a Saudi population.
Allam N; Khalaf H; Fagih M; Al-Sebayel M
Exp Clin Transplant; 2008 Mar; 6(1):14-24. PubMed ID: 18405240
[TBL] [Abstract][Full Text] [Related]
39. Post-transplant inflammatory cytokine signature adds value for predicting tumor recurrence after liver transplantation for hepatocellular carcinoma.
Ng KT; Liu J; Yeung OW; Pang L; Shiu HC; Liu H; Yang XX; Chan AC; Wong TC; Lo CM; Man K
Hepatol Int; 2023 Dec; 17(6):1596-1609. PubMed ID: 37542605
[TBL] [Abstract][Full Text] [Related]
40. Predictive Value of Alpha-fetoprotein in the Survival of Living Donor Liver Transplantation Recipients for Hepatocellular Carcinoma.
Jiang L; Liao A; Yan L; Li B; Zhu W; Wen T
Hepatogastroenterology; 2014 May; 61(131):747-51. PubMed ID: 26176068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
